MARVEL BIOSCIENCES CORP.
$47,000.00
National Research Council Canada | Conseil national de recherches Canada
Industrial Research Assistance Program
FY 2025-2026
Canada
MB-204 is a novel therapeutic candidate with the potential to treat pediatric neurodevelopmental disorders, including Autism, Rett syndrome, and Fragile X syndrome. Many of these patients experience s...